Huangsen Biotechnology

Hangzhou Huangsen Biotechnology is a technology-driven pharmaceutical company founded in 2012 and based in Hangzhou, China. Operating as a wholly-owned subsidiary of Zhejiang Hengkang Pharmaceutical, the company focuses on drug research and development, high-end formulations, and Marketing Authorization Holder (MAH) platform services. Its therapeutic areas of focus include cardiovascular, gastrointestinal, endocrine, and psychiatric disorders. Hangzhou Huangsen Biotechnology has successfully commercialized Amiodarone Hydrochloride Tablets, becoming the first in China to pass the consistency evaluation for this drug, and has a pipeline of generic and improved formulations in various stages of development. Additionally, the company provides integrated contract development and manufacturing organization (CDMO) services for active pharmaceutical ingredients (APIs) and intermediates.